The Emesis (Vomiting) drugs in development market research report provides comprehensive information on the therapeutics under development for Emesis (Vomiting), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Emesis (Vomiting). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Emesis (Vomiting) and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Emesis (Vomiting) by 11 companies/universities/institutes. The top development phase for Emesis (Vomiting) is preclinical with four drugs in that stage. The Emesis (Vomiting) pipeline has 12 drugs in development by companies and one by universities/ institutes. Some of the companies in the Emesis (Vomiting) pipeline products market are: Charleston Laboratories, Neurocrine Biosciences and Daewoo Pharmaceutical.
The key targets in the Emesis (Vomiting) pipeline products market include Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1), Histamine H1 Receptor (HRH1), and D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2).
The key mechanisms of action in the Emesis (Vomiting) pipeline product include Histamine H1 Receptor (HRH1) Antagonist with three drugs in Phase III. The Emesis (Vomiting) pipeline products include eight routes of administration with the top ROA being Oral and two key molecule types in the Emesis (Vomiting) pipeline products market including Small Molecule, and Synthetic Peptide.
Emesis (Vomiting) overview
Emesis (vomiting) is the involuntary, forceful expulsion of the contents of one’s stomach through the mouth and sometimes the nose. Vomiting can be the result of ailments like food poisoning, gastroenteritis, pregnancy, motion sickness, or hangover; or it can be an after effect of diseases such as brain tumors, elevated intracranial pressure, or overexposure to ionizing radiation.
For a complete picture of Emesis (Vomiting)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
